NEW YORK (GenomeWeb News) – The Genome Institute of Singapore and Sengenics said today that they have formed a partnership to identify and validate auto-antibody signatures for the early detection of cancers.

The collaboration will use protein microarray technology from Senegenics' strategic partner, Oxford Gene Technology, and will focus initially on gastric and breast cancers.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: gene linked to expansion of the human neocortex, and more.

The National Institute of General Medical Sciences director says changes the agency made have allow it to boost success rates.

Ancient DNA indicates Stone Age, hunter-gather inhabitants of Britain imported wheat.

Joel Achenbach explores at National Geographic why people find science difficult to believe.